FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: TWO‐YEAR INTERIM RESULTS FROM THE FIGARO STUDY
Introduction: Secondary immunodeficiency diseases (SID) commonly affect patients with hematological malignancies such as chronic lymphocytic leukemia (CLL) and lymphoma. Immunoglobulin replacement therapy (IGRT) is an important therapeutic option for preventing severe, recurrent, or persistent infections in patients with hematologic malignancies and SID. Facilitated subcutaneous immunoglobulin (fSCIG) is a dual-vial unit of immunoglobulin G (IgG) 10% and recombinant human hyaluronidase (rHuPH20) approved in the European Union as an IGRT for patients with SID. rHuPH20 depolymerizes hyaluronan in the extracellular matrix to transiently increase local subcutaneous tissue permeability, allowing for fSCIG infusion at rates, volumes, and frequencies comparable to intravenous immunoglobulin (IVIG) with better systemic tolerability. This study assesses fSCIG usage and tolerability over time in patients with SID seen in routine clinical practice. Methods: FIGARO (NCT03054181) is a European multicenter, prospective, observational study. Patients were eligible if they received ≥1 fSCIG infusion for primary immunodeficiency diseases or SID and provided informed consent. Patients are being followed for up to 3 years. An interim analysis (data cut-off date: February 2, 2021) was conducted to evaluate fSCIG usage and tolerability over the first 2 years of follow up in the subgroup of patients with SID. Results: Of the 156 patients enrolled, 31 (mean [range] age: 61 [3–88] y) had SID and are included in the baseline (inclusion visit) analysis. At interim analysis, 1- and 2-year follow-up data were available for 23 and 12 patients, respectively. Indications for IGRT were CLL (n = 20), non-Hodgkin lymphoma (n = 6), SID due to immunosuppressive therapy (n = 3), and Hodgkin lymphoma (n = 2). At the inclusion visit, fSCIG (median total monthly dose: 30.0 g) was most recently infused at home (61%) or at a hospital (36%) by the patient (58%) or a nurse (42%). Most patients received fSCIG every 4 weeks (68%), infused into a single site. The median maximum infusion rate was consistent over the 2-year follow up: 290 mL/h at inclusion, 268 mL/h at 1 year, and 300 mL/h at 2 years. The median infusion volume was 300 mL across all visits to 2 years, with all patients receiving the full dose as planned. Two patients each reported 1 adverse drug reaction (ADR; erythema and headache) at the inclusion visit, with no ADRs reported at any of the follow-up visits. One patient changed to IVIG by 12 months. Conclusions: In patients with SID primarily due to hematologic malignancies, fSCIG was tolerated over 2-years' follow up in routine clinical practice and offered the flexibility of administration at home or in a hospital setting, either by the patient or a nurse. Infusion parameters remained consistent over time. EA – previously submitted to EHA 2021. The research was funded by: Baxalta Innovations GmbH, a Takeda company, funded this study. Baxalta US Inc., a Takeda company, funded writing support. Keywords: Immunotherapy, Ongoing Trials Conflicts of interests pertinent to the abstract Dör. Huscher Educational grants: has received travel compensation from Actelion Pharmaceuticals, Switzerland, Boehringer-Ingelheim, Germany, and Shire C. Hermann Employment or leadership position: an employee of the Baxalta Innovations GmbH, a member of the Takeda group of companies Stock ownership: a Takeda stock owner D. Pittrow Consultant or advisory role: has acted as consultant for Baxalta Other remuneration: reports personal fees from Actelion, Bayer, Aspen, Boehringer Ingelheim, Sanofi, Biogen, and MSD M. Speletas Research funding: institution has received a research grant from Shire M. Borte Consultant or advisory role: has participated in advisory boards for CSL Behring, Octapharma, and Shire Research funding: institution has received research grant support from CSL Behring, Octapharma, and Baxalta
Read more